The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.

Sponsor: Tanja A. Gruber, MD

Protocol: POE23-01

Principal investigator: Tanja A. Gruber, MD

Site: 27 sites across North America

Estimated accrual years: 5.0